Humedix completes strategic investment in US company Kineta to boost CMO activities


Based on this strategic investment, Kineta has agreed to accelerate the development and commercialization of the company’s immuno-oncology pipeline using Humedix’s production facilities for non-clinical stage manufacturing. In addition, Humedix has secured certain exclusive distribution rights in Korea for products marketed from Kineta’s pipeline currently under development.

Kineta was created in Seattle in 2008 to research and develop new immunotherapies to treat cancer, chronic pain and emerging viruses. Recently, it was recognized for its research and development capabilities by being selected as one of the top 10 immunotherapy companies in 2020 by Pharma Tech Outlook, a global pharmaceutical media.

Jinhwan kim, CEO of Humedix said, “Kineta is a biotechnology company that has been recognized for its technological prowess as it has established strategic alliances with global pharmaceutical companies such as Pfizer and Genentech. With this investment, we plan to continue our partnership on national cooperation for the commercialization of new immuno-oncology drugs. “

“We are delighted to partner with Humedix and leverage their pharmaceutical expertise in the Korean market,” said Dr. Shawn iadona, CEO of Kinéta. “Humedix is ​​a well established and innovative company and we expect our partnership to expand in the future.

NOTICE: This document contains certain forward-looking statements, including, without limitation, statements regarding the plans of Humedix and Kineta for preclinical and clinical studies, regulatory filings, returns on investment and expected drug effects. on human subjects. You are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in the activities of the companies which could significantly affect the expected results, including, without limitation, the progress of development. drugs, the ability to raise capital to fund drug development, clinical trials and regulatory approval, changes in raw material and personnel costs, and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and the companies do not undertake to revise or update any forward-looking statements to reflect events or circumstances after the issuance of this press release.

SOURCE Humedix

Leave A Reply

Your email address will not be published.